MedTrace Logo

Pregabalin Treatment and Prevention Post-herpetic Neuralgia

NCT03186443 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2017-06-14

No results posted yet for this study

Summary

Pregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic neuralgia still need to confirm.

Conditions

  • Herpetic Neuralgia

Interventions

DRUG

Pregabalin

Pregabalin was taken 300mg,q 12h for 6 month.

DRUG

Gabapentin

Gabapentin was taken 0.4, tid for 6 month.

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Nanjing PLA General Hospital

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Second Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Li Wan, Ph.D.,M.D. · The Second Affiliated Hospital, Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2017-10-01
Completion
2017-10-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03186443 on ClinicalTrials.gov